JP2025503470A5 - - Google Patents
Info
- Publication number
- JP2025503470A5 JP2025503470A5 JP2024537410A JP2024537410A JP2025503470A5 JP 2025503470 A5 JP2025503470 A5 JP 2025503470A5 JP 2024537410 A JP2024537410 A JP 2024537410A JP 2024537410 A JP2024537410 A JP 2024537410A JP 2025503470 A5 JP2025503470 A5 JP 2025503470A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- fusion protein
- protein
- lacks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291565P | 2021-12-20 | 2021-12-20 | |
| US63/291,565 | 2021-12-20 | ||
| PCT/US2022/081912 WO2023122523A1 (en) | 2021-12-20 | 2022-12-19 | Compositions and methods for expressing antigens on cell membrane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503470A JP2025503470A (ja) | 2025-02-04 |
| JP2025503470A5 true JP2025503470A5 (https=) | 2025-12-08 |
Family
ID=85174035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537410A Pending JP2025503470A (ja) | 2021-12-20 | 2022-12-19 | 細胞膜上に抗原を発現させるための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250057937A1 (https=) |
| EP (1) | EP4453009A1 (https=) |
| JP (1) | JP2025503470A (https=) |
| KR (1) | KR20240109612A (https=) |
| CN (1) | CN118414349A (https=) |
| AU (1) | AU2022419507A1 (https=) |
| CA (1) | CA3242553A1 (https=) |
| CL (1) | CL2024001834A1 (https=) |
| CO (1) | CO2024007501A2 (https=) |
| CR (1) | CR20240249A (https=) |
| DK (1) | DK202470171A1 (https=) |
| MX (1) | MX2024007697A (https=) |
| WO (1) | WO2023122523A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208157A1 (en) | 2020-09-04 | 2023-07-12 | Elanco Us Inc. | Palatable formulations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440513A1 (en) * | 2001-03-05 | 2002-09-12 | The State Of Oregon Acting By And Through The State Board Of Higher Educ Ation On Behalf Of Oregon State University | Nucleic acids for transforming fish cells and methods for their use |
| GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| GB201415789D0 (en) | 2014-09-05 | 2014-10-22 | Touchlight Genetics Ltd | Synthesis of DNA |
| US10456459B2 (en) | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| CN109844134B (zh) | 2016-08-16 | 2023-05-05 | 塔驰莱特Ip有限公司 | 闭合线性dna的生产 |
| GB2559193A (en) * | 2017-01-31 | 2018-08-01 | Pharmaq As | Virus-like particle |
| GB201805683D0 (en) | 2018-04-05 | 2018-05-23 | Touchlight Ip Ltd | Reprogramming vectors |
| GB201816873D0 (en) * | 2018-10-17 | 2018-11-28 | Imperial Innovations Ltd | Fusion protein |
| GB202002068D0 (en) | 2020-02-14 | 2020-04-01 | Touchlight Ip Ltd | DNA synthesis yield improvements |
-
2022
- 2022-12-19 CN CN202280084451.0A patent/CN118414349A/zh active Pending
- 2022-12-19 CR CR20240249A patent/CR20240249A/es unknown
- 2022-12-19 MX MX2024007697A patent/MX2024007697A/es unknown
- 2022-12-19 US US18/721,713 patent/US20250057937A1/en active Pending
- 2022-12-19 JP JP2024537410A patent/JP2025503470A/ja active Pending
- 2022-12-19 AU AU2022419507A patent/AU2022419507A1/en active Pending
- 2022-12-19 KR KR1020247020614A patent/KR20240109612A/ko active Pending
- 2022-12-19 CA CA3242553A patent/CA3242553A1/en active Pending
- 2022-12-19 EP EP22854442.5A patent/EP4453009A1/en active Pending
- 2022-12-19 WO PCT/US2022/081912 patent/WO2023122523A1/en not_active Ceased
-
2024
- 2024-06-14 CO CONC2024/0007501A patent/CO2024007501A2/es unknown
- 2024-06-18 CL CL2024001834A patent/CL2024001834A1/es unknown
- 2024-06-19 DK DKPA202470171A patent/DK202470171A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1097213B1 (en) | Vaccine against staphylococcus intoxication | |
| Kortekaas et al. | Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector | |
| US20050002953A1 (en) | SARS-coronavirus virus-like particles and methods of use | |
| JP2025503468A5 (https=) | ||
| US20250127873A1 (en) | Compositions and methods for prevention of piscine myocarditis | |
| JP6990814B2 (ja) | アヒル腸炎ウイルス及びその使用 | |
| US20250057946A1 (en) | Use of interferon as an adjuvant in vaccines | |
| JP2025501740A5 (https=) | ||
| Kim et al. | Protection against very virulent infectious bursal disease virus in chickens immunized with DNA vaccines | |
| US20230144060A1 (en) | MERS-CoV VACCINE | |
| JP2025503470A5 (https=) | ||
| TWI342783B (en) | Safe mutant viral vaccines | |
| AU2018383915B2 (en) | Multivalent feline vaccine | |
| Kim et al. | Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG) | |
| US20250057937A1 (en) | Compositions and methods for expressing antigens on cell membrane | |
| JP6373601B2 (ja) | アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド | |
| CA2378437A1 (en) | Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines | |
| RU2854997C2 (ru) | Использование интерферона в качестве адьюванта в вакцинах | |
| RU2024116751A (ru) | Композиции и способы экспрессии антигенов на клеточной мембране | |
| RU2024116753A (ru) | Использование интерферона в качестве адьюванта в вакцинах | |
| RU2797538C2 (ru) | Поливалентная вакцина для животных семейства кошачьих | |
| Phuoc et al. | EXPRESSION OF HAEMAGGLUTININ-NEURAMINIDASE OF NEWCASTLE VIRUS GENOTYPE VIII IN INSECT CELL SF9. | |
| WO2024073766A2 (en) | Safe, diva-compatible, subunit vaccine for african swine fever virus | |
| Echanove Juan | Development of a novel DNA vaccine platform using viral-and vector-derived antigens to prevent Crimean-Congo hemorrhagic fever | |
| Man | Expression of haemagglutinin-neuraminidase of newcastle virus genotype VIII in insect cell Sf9 |